CSL Behring Announces the 2014 Interlaken Leadership Awards Recipient

    CSL Behring Announces the 2014 Interlaken Leadership Awards Recipient

Interlaken Leadership Awards Program Supports Original Research in the Field
of Neuroimmunology

PR Newswire

KING OF PRUSSIA, Pa., June 24, 2014

KING OF PRUSSIA, Pa., June 24, 2014 /PRNewswire/ --CSL Behring announced
today that Bart C. Jacobs, M.D., Ph.D., Erasmus University Medical Center,
Rotterdam, Netherlands, is the recipient of the 2014 Interlaken Leadership
Awards for original research in the field of neuroimmunology. Established in
2010, this annual global awards program provides monetary grants and/or
product supply for investigational use to researchers whose proposals are
likely to advance innovative medical research and knowledge about the
potential role of immunoglobulin (Ig) therapy in the treatment of neurological

A global, cross-functional CSL Behring review committee selected Dr. Jacobs'
proposal to investigate the efficacy of intravenous immunoglobulin (IVIg)
treatment in patients with mild Guillain-Barre syndrome (GBS). GBS is an
inflammatory disorder of the peripheral nerves characterized by the rapid
onset of weakness and, often, paralysis of the legs, arms, breathing muscles
and face. While IVIg is recommended in severe GBS, current guidelines
recommend providing supportive care only to those with mild forms of GBS.

"Recent studies have demonstrated that a considerable proportion of untreated
patients with mild Guillain-Barre syndrome have persistent disability, severe
residual fatigue and pain, and poor quality of life, and my hypotheses is that
IVIg may improve disease in these patients," said Dr. Jacobs. "I am honored to
have been selected by CSL Behring to receive the Interlaken Leadership Award,
and look forward to continuing research into whether IVIg may improve outcomes
for those with mild GBS."

All proposals received for the Interlaken Leadership Awards program were
evaluated based on scientific merit, strength of hypothesis, relevance to
neuroimmunology and feasibility.

"The Interlaken Leadership Awards underpins CSL Behring's commitment to saving
lives and improving the quality of life for people with rare and serious
diseases worldwide by funding innovative research that could lead to the
discovery of new treatment options for people who are living with a
neurological disorder," said Bernadine Dixon, Senior Director, Immunology and
Pulmonary, CSL Behring. "We look forward to the results of Dr. Jacobs'
research evaluating the potential use of IVIg for treatment of mild
Guillain-Barre syndrome, as well as to supporting further original research in
the field of neuroimmunology through the Interlaken Leadership Awards."

To date, the Interlaken Leadership Awards has awarded approximately $3.5
million in grants and/or study drug for research studying Ig therapy in areas
such as neuromyelitis optica (NMO), Duchenne muscular dystrophy (DMD), complex
regional pain syndrome (CRPS), paraneoplastic syndromes, and autoimmune
peripheral neuropathies.

About the International Immunoglobulin Conference in Interlaken
For more than three decades, CSL Behring has sponsored a high-level scientific
symposium in Interlaken, Switzerland. First held in 1981, and most recently in
April 2014, the International Immunoglobulin Conference focuses exclusively on
scientific and clinical research in the field of polyvalent immunoglobulins.

Research presented at the Interlaken Immunoglobulin Conference is consistently
at the forefront of immunoglobulin research. Since its inception, the
conference has won the respect and support of top international scientists and
clinicians from many different fields of research. For more information,
please visit: http://www.interlakenleadershipawards.com/symposium.aspx.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed
to saving lives and improving the quality of life for people with rare and
serious diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders
including hemophilia and von Willebrand disease, primary immune deficiencies,
hereditary angioedema and inherited respiratory disease, and neurological
disorders in certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent hemolytic
diseases in the newborn. CSL Behring operates one of the world's largest
plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL
Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne,
Australia. For more information, visit http://www.cslbehring.com/.

Media Contact:
Greg Healy
Senior Manager, Public Relations & Communications
CSL Behring


Website: http://www.cslbehring.com
Website: http://www.interlakenleadershipawards.com
Press spacebar to pause and continue. Press esc to stop.